Glecaprevir/pibrentasvir Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Glecaprevir/pibrentasvir comprises 53 peer-reviewed publications across 15 journals, 22 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Hepatitis C, and Hepatitis C, Chronic. Most recent publication: Population Pharmacokinetic Analysis of Glecaprevir and Pibrentasvir in Pediatric Patients ≥ 3 to < 18 Years of Age with Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection., Clin Pharmacokinet, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Four-Week Direct-Acting Antiviral Prophylaxis for Kidney Transplantation From Hepatitis C-Viremic Donors to Hepatitis C-Negative Recipients: An Open-Label Nonrandomized Study.
    Durand CM, Barnaba B, Yu S, et al. · Ann Intern Med · 2021
    PubMed: PMID 32894697 · NCT04575896 · Hepatitis C
  2. Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2).
    Wei L, Wang G, Alami NN, et al. · Lancet Gastroenterol Hepatol · 2020
    PubMed: PMID 32682494 · NCT03235349 (VOYAGE-2) · Hepatitis C
  3. Population Pharmacokinetic Analysis of Glecaprevir and Pibrentasvir in Pediatric Patients ≥ 3 to < 18 Years of Age with Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection.
    Thakre N, Beck D, Saeed AM, et al. · Clin Pharmacokinet · 2026
    PubMed: PMID 42189498 · NCT03067129 (DORA) · Hepatitis C
  4. A single-arm phase IIIb study of 8-week glecaprevir/pibrentasvir treatment in adults with acute hepatitis C.
    Llibre JM, Boesecke C, Moon J, et al. · J Hepatol · 2026
    PubMed: PMID 41297677 · NCT04903626 · Hepatitis C
  5. Short Course Therapy With Glecaprevir/Pibrentasvir for Early Hepatitis C Virus Infection: PURGE-C.
    Kim AY, Kang M, Umbleja T, et al. · Clin Infect Dis · 2026
    PubMed: PMID 40736252 · NCT04042740 (PURGE-C) · Hepatitis C
  6. A point-of-care testing intervention to improve hepatitis C diagnosis and treatment uptake among people attending Aboriginal community controlled health services: the SCALE-C study.
    Hosseini-Hooshyar S, Valerio H, Flynn E, et al. · BMC Infect Dis · 2025
    PubMed: PMID 41250046 · NCT03776760 (SCALE-C) · Hepatitis C
  7. Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study.
    Feld JJ, Cypel M, Kumar D, et al. · Lancet Gastroenterol Hepatol · 2020
    PubMed: PMID 32389183 · NCT04017338 · Hepatitis C
  8. Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients with Evidence of Portal Hypertension.
    Brown RS, Collins MA, Strasser SI, et al. · Infect Dis Ther · 2024
    PubMed: PMID 35174470 · NCT02966795 (ENDURANCE-5 6) · Hepatitis C

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT02692703Hepatitis CPercentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
12 weeks after the last dose of study drug (up to 24 weeks)
Glecaprevir/Pibrentasvir98 percentage of participants
NCT02939989
MAGELLAN-3
Hepatitis CPercentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
12 weeks after the last actual dose of study drug, Week 24 or Week 28 depending on the treatment regimen.
Glecaprevir/Pibrentasvir + SOF + RBV for 12 Weeks100 percentage of participants
Glecaprevir/Pibrentasvir + SOF + RBV for 16 Weeks96.4 percentage of participants
Total97.0 percentage of participants
NCT02966795
ENDURANCE-5 6
Hepatitis CPercentage of Participants With Sustained Virologic Response 12 Weeks Post Treatment (SVR12)
12 weeks after last dose of study drug (week 20 or 24 depending on the treatment regimen)
Genotype 5-infected95.7 percentage of participants
Genotype 6-infected98.4 percentage of participants
NCT03067129
DORA
Hepatitis CPercentage of Participants With Sustained Virologic Response 12 Weeks Post Treatment (SVR12)
12 weeks after last dose of study drug (Week 20, 24, or 28 depending on treatment duration)
Cohort 1: Adult Formulation GLE/PIB; 12 to < 18 Years100 percentage of participants
Cohort 2: Pediatric Formulation GLE + PIB; 9 to < 12 Years93.1 percentage of participants
Cohort 3: Pediatric Formulation GLE + PIB; 6 to < 9 Years100 percentage of participants
Cohort 4: Pediatric Formulation GLE + PIB; 3 to < 6 Years95.8 percentage of participants
Cohorts 2-4: Pediatric Formulation GLE + PIB; 3 to < 12 Years96.3 percentage of participants
Total97.6 percentage of participants
NCT03067129
DORA
Hepatitis CSteady-state Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours Postdose (AUC0-24) of Glecaprevir
Week 2 from predose to 24 hours post-dose
Cohort 1: Adult Formulation GLE/PIB; 12 to < 18 Years4790 ng*h/mL
Cohort 2: Pediatric Formulation GLE + PIB; 9 to < 12 Years7870 ng*h/mL
Cohort 3: Pediatric Formulation GLE + PIB; 6 to < 9 Years6860 ng*h/mL
Cohort 4: Pediatric Formulation GLE + PIB; 3 to < 6 Years7520 ng*h/mL
NCT03067129
DORA
Hepatitis CSteady-state AUC0-24 of Pibrentasvir
Week 2 from predose to 24 hours post-dose
Cohort 1: Adult Formulation GLE/PIB; 12 to < 18 Years1380 ng*h/mL
Cohort 2: Pediatric Formulation GLE + PIB; 9 to < 12 Years2200 ng*h/mL
Cohort 3: Pediatric Formulation GLE + PIB; 6 to < 9 Years1640 ng*h/mL
Cohort 4: Pediatric Formulation GLE + PIB; 3 to < 6 Years1790 ng*h/mL
NCT03069365
EXPEDITION-5
Hepatitis CPercentage of Participants Achieving Sustained Virologic Response 12 Weeks Post Dosing (SVR12)
12 weeks after the last actual dose of study drug
GLE/PIB for 8, 12, or 16 Weeks97.0 percentage of participants
NCT03089944
EXPEDITION-8
Hepatitis CPercentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Hepatitis C Virus (HCV) Genotype (GT) 1,2,4,5 and 6-infected Participants in the Per Protocol (PP) Population
12 weeks after last dose of study drug
Glecaprevir (GLE)/Pibrentasvir (PIB) for 8 Weeks100 percentage of participants
NCT03089944
EXPEDITION-8
Hepatitis CPercentage of Participants With SVR12 in HCV GT 1,2,4,5 and 6-infected Participants in the Intent-To-Treat (ITT) Population
12 weeks after last dose of study drug
Glecaprevir (GLE)/Pibrentasvir (PIB) for 8 Weeks98.2 percentage of participants
NCT03092375Hepatitis CComparison of Cirrhotic Participants Achieving SVR 12 After G/P Plus RBV for 12 Wks vs. G/P for 16 Wks
Up to 28 weeks
Arm C: G/P 300 mg/120 mg QD + RBV 12 Wks18 Participants
Arm C: G/P 300 mg/120 mg QD + RBV 12 Wks3 Participants
Arm D: G/P 300 mg/120 mg QD for 16 Wks28 Participants
Arm D: G/P 300 mg/120 mg QD for 16 Wks1 Participants
NCT03092375Hepatitis CSVR After G/P 12 Wks (Arm A) vs. G/P Given for 16 Weeks (Arm B) to Non-cirrhotic Treatment-experienced GT1 HCV Participants
Up to 28 weeks
Arm A: G/P 300 mg/120 mg QD for 12 Wks70 Participants
Arm A: G/P 300 mg/120 mg QD for 12 Wks8 Participants
Arm B: G/P 300 mg/120 mg QD for 16 Wks46 Participants
Arm B: G/P 300 mg/120 mg QD for 16 Wks3 Participants
NCT03092375Hepatitis CTolerability of G/P +/-RBV
Up to 16 weeks
Arm A: G/P 300 mg/120 mg QD for 12 Wks0 Participants
Arm B: G/P 300 mg/120 mg QD for 16 Wks0 Participants
Arm C: G/P 300 mg/120 mg QD + RBV 12 Wks0 Participants
Arm D: G/P 300 mg/120 mg QD for 16 Wks0 Participants
NCT03117569
SMART-C
Hepatitis C, ChronicUndetectable HCV RNA (ITT Population)
12 weeks post end of treatment (SVR12)
Simplified Monitoring Schedule233 Participants
Standard Monitoring Schedule121 Participants
NCT03212521Hepatitis CPercentage of Participants in the Modified Intention-to-Treat Population With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
12 weeks after the last actual dose of study drug, Week 20
Glecaprevir/Pibrentasvir100.0 percentage of participants
NCT03219216Hepatitis CPercentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
12 weeks after last dose of study drug (week 20 or 24 depending on treatment regimen)
All Participants98.0 percentage of participants
NCT03222583
VOYAGE-1
Hepatitis CPercentage of HCV GT1-Infected Participants in Arm A Who Achieved SVR12
12 weeks after last actual dose of study drug, Week 20 or Week 28 depending on the treatment regimen
Arm A: Glecaprevir/Pibrentasvir99.4 percentage of participants
NCT03222583
VOYAGE-1
Hepatitis CPercentage of HCV GT1 - GT6-Infected Participants in Arm A Who Achieved Sustained Virologic Response 12 Weeks Post Treatment (SVR12)
12 weeks after the last actual dose of study drug, Week 20 or Week 28 depending on the treatment regimen.
Arm A: Glecaprevir/Pibrentasvir97.2 percentage of participants
NCT03222583
VOYAGE-1
Hepatitis CPercentage of HCV GT2-Infected Participants in Arm A Who Achieved SVR12
12 weeks after the last dose of study drug, Week 20 or Week 28 depending on the treatment regimen.
Arm A: Glecaprevir/Pibrentasvir97.8 percentage of participants
NCT03235349
VOYAGE-2
Hepatitis CPercentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
12 weeks after the last actual dose of study drug, Week 24 or Week 28 depending on the treatment regimen.
Glecaprevir/Pibrentasvir99.4 percentage of participants
NCT03801707Hepatitis CElevation in Liver Enzyme >5 Times the Upper Limits, Development of Acute Cholestatic Hepatitis , or Intolerance to Direct Acting Antiviral Therapies
12 weeks
Intervention Group2 Participants
Intervention Group0 Participants
Intervention Group0 Participants
Intervention Group28 Participants
NCT03801707Hepatitis CProportion of Patients With Undetectable Hepatitis C Virus (HCV) Polymerase Chain Reaction (PCR) at 12 Weeks After Completion of HCV Treatment
12 weeks
Intervention Group28 Participants
NCT04903626Hepatitis CPercentage of Participants Achieving Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in the Intention-to-Treat (ITT) Population
12 weeks after last dose of study treatment (Week 20)
Glecaprevir/Pibrentasvir96.2 percentage of participants

Publications by year

2007–2026: 53 publications.

2007
1
2012
1
2016
4
2017
3
2019
9
2020
9
2021
10
2022
8
2023
2
2024
1
2025
1
2026
4

Publications by indication

Hepatitis C (52)

  • Population Pharmacokinetic Analysis of Glecaprevir and Pibrentasvir in Pediatric Patients ≥ 3 to < 18 Years of Age with Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection.
    Clin Pharmacokinet · 2026 · PMID 42189498 · NCT03067129
  • A single-arm phase IIIb study of 8-week glecaprevir/pibrentasvir treatment in adults with acute hepatitis C.
    J Hepatol · 2026 · PMID 41297677 · NCT04903626
  • Short Course Therapy With Glecaprevir/Pibrentasvir for Early Hepatitis C Virus Infection: PURGE-C.
    Clin Infect Dis · 2026 · PMID 40736252 · NCT04042740
  • Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.
    Clin Infect Dis · 2026 · PMID 37229695 · NCT06367465
  • A point-of-care testing intervention to improve hepatitis C diagnosis and treatment uptake among people attending Aboriginal community controlled health services: the SCALE-C study.
    BMC Infect Dis · 2025 · PMID 41250046 · NCT03776760

Hepatitis C, Chronic (1)

  • Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.
    J Hepatol · 2021 · PMID 31655134 · NCT03117569

Publications by journal

Trial-results highlights

Clinical trials have evaluated the effectiveness of glecaprevir/pibrentasvir in treating Hepatitis C. In NCT02692703, 98 percentage of participants treated with Glecaprevir/Pibrentasvir achieved sustained virologic response 12 weeks post-treatment (SVR12). The MAGELLAN-3 study (NCT02939989) reported that 100 percentage of participants who received Glecaprevir/Pibrentasvir + SOF + RBV for 12 weeks achieved SVR12, while 96.4 percentage of participants in the 16-week regimen arm achieved SVR12, with a total of 97.0 percentage of participants across both arms. In NCT03069365 (EXPEDITION-5), 97.0 percentage of participants receiving GLE/PIB for 8, 12, or 16 weeks achieved SVR12. Furthermore, in NCT03089944 (EXPEDITION-8), 100 percentage of participants treated with Glecaprevir (GLE)/Pibrentasvir (PIB) for 8 weeks achieved SVR12.

Specific genotypes were also studied. In the ENDURANCE-5 6 trial (NCT02966795), 95.7 percentage of participants with Genotype 5-infected Hepatitis C achieved SVR12, and 98.4 percentage of participants with Genotype 6-infected Hepatitis C achieved SVR12. The DORA study (NCT03067129) investigated glecaprevir/pibrentasvir in pediatric populations for SVR12.

  • Cohort 1 (Adult Formulation GLE/PIB; 12 to < 18 Years): 100 percentage of participants
  • Cohort 2 (Pediatric Formulation GLE + PIB; 9 to < 12 Years): 93.1 percentage of participants
  • Cohort 3 (Pediatric Formulation GLE + PIB; 6 to < 9 Years): 100 percentage of participants
  • Cohort 4 (Pediatric Formulation GLE + PIB; 3 to < 6 Years): 95.8 percentage of participants
For Cohorts 2-4 combined, 96.3 percentage of participants achieved SVR12, with a total of 97.6 percentage of participants across all cohorts in NCT03067129. This study also reported steady-state area under the plasma concentration-time curve from time zero to 24 hours postdose (AUC0-24) at Week 2.
  • For glecaprevir AUC0-24:
    • Cohort 1: 4790 ng*h/mL
    • Cohort 2: 7870 ng*h/mL
    • Cohort 3: 6860 ng*h/mL
    • Cohort 4: 7520 ng*h/mL
  • For pibrentasvir AUC0-24:
    • Cohort 1: 1380 ng*h/mL
    • Cohort 2: 2200 ng*h/mL
    • Cohort 3: 1640 ng*h/mL
    • Cohort 4: 1790 ng*h/mL

All values are sourced from primary registry reporting; individual papers should be consulted for clinical decisions.

All Glecaprevir/pibrentasvir publications (53)

2026 (4 papers)

  1. Population Pharmacokinetic Analysis of Glecaprevir and Pibrentasvir in Pediatric Patients ≥ 3 to < 18 Years of Age with Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection.
    Thakre N, Beck D, Saeed AM, et al. · Clin Pharmacokinet · 2026 · Derived
    PubMed: PMID 42189498 · NCT03067129 (DORA) · Hepatitis C
  2. A single-arm phase IIIb study of 8-week glecaprevir/pibrentasvir treatment in adults with acute hepatitis C.
    Llibre JM, Boesecke C, Moon J, et al. · J Hepatol · 2026 · Derived
    PubMed: PMID 41297677 · NCT04903626 · Hepatitis C
  3. Short Course Therapy With Glecaprevir/Pibrentasvir for Early Hepatitis C Virus Infection: PURGE-C.
    Kim AY, Kang M, Umbleja T, et al. · Clin Infect Dis · 2026 · Derived
    PubMed: PMID 40736252 · NCT04042740 (PURGE-C) · Hepatitis C
  4. Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.
    Bhattacharya D, Aronsohn A, Price J, et al. · Clin Infect Dis · 2026 · Background
    PubMed: PMID 37229695 · NCT06367465 · Hepatitis C

2025 (1 paper)

  1. A point-of-care testing intervention to improve hepatitis C diagnosis and treatment uptake among people attending Aboriginal community controlled health services: the SCALE-C study.
    Hosseini-Hooshyar S, Valerio H, Flynn E, et al. · BMC Infect Dis · 2025 · Derived
    PubMed: PMID 41250046 · NCT03776760 (SCALE-C) · Hepatitis C

2024 (1 paper)

  1. Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients with Evidence of Portal Hypertension.
    Brown RS, Collins MA, Strasser SI, et al. · Infect Dis Ther · 2024 · Derived
    PubMed: PMID 35174470 · NCT02966795 (ENDURANCE-5 6) · Hepatitis C

2023 (2 papers)

  1. Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D study.
    Martinello M, Bhagani S, Shaw D, et al. · JHEP Rep · 2023 · Derived
    PubMed: PMID 37771545 · NCT02634008 (TARGET3D) · Hepatitis C
  2. Single-visit hepatitis C point-of-care testing, linkage to nursing care, and peer-supported treatment among people with recent injecting drug use at a peer-led needle and syringe program: The TEMPO Pilot Study.
    Grebely J, Gilliver R, McNaughton T, et al. · Int J Drug Policy · 2023 · Derived
    PubMed: PMID 36863287 · NCT03492112 (TEMPO) · Hepatitis C

2022 (8 papers)

  1. Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvir.
    Wang GP, Schnell GL, Kort JJ, et al. · J Hepatol · 2022 · Derived
    PubMed: PMID 34023351 · NCT03092375 · Hepatitis C
  2. One-Year Outcomes of the Multi-Center StudY to Transplant Hepatitis C-InfeCted kidneys (MYTHIC) Trial.
    Sise ME, Goldberg DS, Schaubel DE, et al. · Kidney Int Rep · 2022 · Derived
    PubMed: PMID 35155863 · NCT03781726 (MYTHIC) · Hepatitis C
  3. Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Children With Chronic HCV: Part 2 of the DORA Study.
    Jonas MM, Rhee S, Kelly DA, et al. · Hepatology · 2022 · Derived
    PubMed: PMID 33811356 · NCT03067129 (DORA) · Hepatitis C
  4. Sofosbuvir-based therapy for late pregnant women and infants with severe chronic hepatitis C: A case series study.
    Zeng QL, Yu ZJ, Lv J, et al. · J Med Virol · 2022 · Background
    PubMed: PMID 35595682 · NCT06367465 · Hepatitis C
  5. Treatment of Women With Hepatitis C Diagnosed in Pregnancy: a Co-Located Treatment Approach.
    Kushner T, Lange M, Sperling R, et al. · Gastroenterology · 2022 · Background
    PubMed: PMID 35863531 · NCT06367465 · Hepatitis C
  6. Postpartum Follow-up Care for Pregnant Persons With Opioid Use Disorder and Hepatitis C Virus Infection.
    Jarlenski M, Chen Q, Ahrens KA, et al. · Obstet Gynecol · 2022 · Background
    PubMed: PMID 35576352 · NCT06367465 · Hepatitis C
  7. Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study.
    Chappell CA, Scarsi KK, Kirby BJ, et al. · Lancet Microbe · 2022 · Background
    PubMed: PMID 32939459 · NCT06367465 · Hepatitis C
  8. Pragmatic Experience with Risk-based versus Universal Hepatitis C Screening in Pregnancy: Detection of Infection and Postpartum Linkage to Care.
    Bushman ET, Subramani L, Sanjanwala A, et al. · Am J Perinatol · 2022 · Background
    PubMed: PMID 33934324 · NCT06367465 · Hepatitis C

2021 (10 papers)

  1. Four-Week Direct-Acting Antiviral Prophylaxis for Kidney Transplantation From Hepatitis C-Viremic Donors to Hepatitis C-Negative Recipients: An Open-Label Nonrandomized Study.
    Durand CM, Barnaba B, Yu S, et al. · Ann Intern Med · 2021 · Trial result
    PubMed: PMID 32894697 · NCT04575896 · Hepatitis C
  2. Efficacy and safety of glecaprevir/pibrentasvir in treatment-naïve adults with chronic hepatitis C virus genotypes 1-6 in Brazil.
    Peribañez-Gonzalez M, Cheinquer H, Rodrigues L, et al. · Ann Hepatol · 2021 · Derived
    PubMed: PMID 32949786 · NCT03219216 · Hepatitis C
  3. Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals.
    Liu CH, Lee MH, Lin JW, et al. · J Hepatol · 2021 · Derived
    PubMed: PMID 31790766 · NCT04047680 · Hepatitis C
  4. Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection.
    Lawitz E, Flisiak R, Abunimeh M, et al. · Liver Int · 2021 · Derived
    PubMed: PMID 31821716 · NCT03069365 (EXPEDITION-5) · Hepatitis C
  5. Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.
    Dore GJ, Feld JJ, Thompson A, et al. · J Hepatol · 2021 · Derived
    PubMed: PMID 31655134 · NCT03117569 (SMART-C) · Hepatitis C, Chronic
  6. Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.
    Brown RS, Buti M, Rodrigues L, et al. · J Hepatol · 2021 · Derived
    PubMed: PMID 31682879 · NCT03089944 (EXPEDITION-8) · Hepatitis C
  7. Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection.
    Sise ME, Goldberg DS, Kort JJ, et al. · J Am Soc Nephrol · 2021 · Background
    PubMed: PMID 32843477 · NCT04614142 · Hepatitis C
  8. Ultra-short duration direct acting antiviral prophylaxis to prevent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant recipients.
    Gupta G, Yakubu I, Bhati CS, et al. · Am J Transplant · 2021 · Background
    PubMed: PMID 31652392 · NCT04596475 · Hepatitis C
  9. Utilization of hepatitis C virus-infected organ donors in cardiothoracic transplantation: An ISHLT expert consensus statement.
    Aslam S, Grossi P, Schlendorf KH, et al. · J Heart Lung Transplant · 2021 · Background
    PubMed: PMID 32362393 · NCT04596475 · Hepatitis C
  10. Pregnancy outcome of anti-HCV direct-acting antivirals: Real-life data from an Egyptian cohort.
    AbdAllah M, Alboraie M, Abdel-Razek W, et al. · Liver Int · 2021 · Background
    PubMed: PMID 33905164 · NCT06367465 · Hepatitis C

2020 (9 papers)

  1. Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2).
    Wei L, Wang G, Alami NN, et al. · Lancet Gastroenterol Hepatol · 2020 · Derived
    PubMed: PMID 32682494 · NCT03235349 (VOYAGE-2) · Hepatitis C
  2. Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Virus: Part 1 of the DORA Study.
    Jonas MM, Squires RH, Rhee SM, et al. · Hepatology · 2020 · Derived
    PubMed: PMID 31254392 · NCT03067129 (DORA) · Hepatitis C
  3. Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study.
    Fontana RJ, Lens S, McPherson S, et al. · Adv Ther · 2020 · Derived
    PubMed: PMID 31646465 · NCT03212521 · Hepatitis C
  4. Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study.
    Feld JJ, Cypel M, Kumar D, et al. · Lancet Gastroenterol Hepatol · 2020 · Derived
    PubMed: PMID 32389183 · NCT04017338 · Hepatitis C
  5. Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection.
    Wyles D, Weiland O, Yao B, et al. · J Hepatol · 2020 · Background
    PubMed: PMID 30857780 · NCT02939989 (MAGELLAN-3) · Hepatitis C
  6. Reported Prevalence of Maternal Hepatitis C Virus Infection in the United States.
    Rossi RM, Wolfe C, Brokamp R, et al. · Obstet Gynecol · 2020 · Background
    PubMed: PMID 31923064 · NCT06367465 · Hepatitis C
  7. Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors.
    Kwong AJ, Wall A, Melcher M, et al. · Am J Transplant · 2020 · Background
    PubMed: PMID 30378723 · NCT04596475 · Hepatitis C
  8. Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study.
    Bethea ED, Gaj K, Gustafson JL, et al. · Lancet Gastroenterol Hepatol · 2020 · Background
    PubMed: PMID 31353243 · NCT04596475 · Hepatitis C
  9. Outcomes of heart transplantation from hepatitis C virus-positive donors.
    Aslam S, Yumul I, Mariski M, et al. · J Heart Lung Transplant · 2020 · Background
    PubMed: PMID 31521479 · NCT04596475 · Hepatitis C

2019 (9 papers)

  1. Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy.
    Lok AS, Sulkowski MS, Kort JJ, et al. · Gastroenterology · 2019 · Derived
    PubMed: PMID 31401140 · NCT03092375 · Hepatitis C
  2. Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients.
    Woolley AE, Singh SK, Goldberg HJ, et al. · N Engl J Med · 2019 · Background
    PubMed: PMID 30946553 · NCT04596475 · Hepatitis C
  3. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.
    Reau N, Kwo PY, Rhee S, et al. · Hepatology · 2019 · Background
    PubMed: PMID 29672891 · NCT02692703 · Hepatitis C
  4. OPTN/SRTR 2016 Annual Data Report: Kidney.
    Hart A, Smith JM, Skeans MA, et al. · Am J Transplant · 2019 · Background
    PubMed: PMID 29292608 · NCT03801707 · Hepatitis C
  5. Perinatal Transmission of Hepatitis C Virus: Defining the Cascade of Care.
    Epstein RL, Sabharwal V, Wachman EM, et al. · J Pediatr · 2019 · Background
    PubMed: PMID 30170857 · NCT06367465 · Hepatitis C
  6. Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.
    Durand CM, Bowring MG, Brown DM, et al. · Ann Intern Med · 2019 · Background
    PubMed: PMID 29507971 · NCT03801707 · Hepatitis C
  7. Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial.
    Asselah T, Lee SS, Yao BB, et al. · Lancet Gastroenterol Hepatol · 2019 · Background
    PubMed: PMID 30393106 · NCT02966795 (ENDURANCE-5 6) · Hepatitis C
  8. Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients.
    Agarwal K, Castells L, Müllhaupt B, et al. · J Hepatol · 2019 · Background
    PubMed: PMID 29886154 · NCT03801707 · Hepatitis C
  9. ACOG Committee Opinion No. 736: Optimizing Postpartum Care.
    Obstet Gynecol · 2019 · Background
    PubMed: PMID 29683911 · NCT06367465 · Hepatitis C

2017 (3 papers)

  1. Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials.
    Younossi ZM, Stepanova M, Sulkowski M, et al. · Clin Infect Dis · 2017 · Background
    PubMed: PMID 27444413 · NCT03801707 · Hepatitis C
  2. Predictors of Non-Attendance to the Postpartum Follow-up Visit.
    Wilcox A, Levi EE, Garrett JM, et al. · Matern Child Health J · 2017 · Background
    PubMed: PMID 27562797 · NCT06367465 · Hepatitis C
  3. Trial of Transplantation of HCV-Infected Kidneys into Uninfected Recipients.
    Goldberg DS, Abt PL, Blumberg EA, et al. · N Engl J Med · 2017 · Background
    PubMed: PMID 28459186 · NCT04614142 · Hepatitis C

2016 (4 papers)

  1. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.
    Foster GR, Afdhal N, Roberts SK, et al. · N Engl J Med · 2016 · Background
    PubMed: PMID 26575258 · NCT03801707 · Hepatitis C
  2. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.
    Feld JJ, Moreno C, Trinh R, et al. · J Hepatol · 2016 · Background
    PubMed: PMID 26476290 · NCT03801707 · Hepatitis C
  3. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.
    Feld JJ, Jacobson IM, Hézode C, et al. · N Engl J Med · 2016 · Background
    PubMed: PMID 26571066 · NCT03801707 · Hepatitis C
  4. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.
    Curry MP, O'Leary JG, Bzowej N, et al. · N Engl J Med · 2016 · Background
    PubMed: PMID 26569658 · NCT03801707 · Hepatitis C

2012 (1 paper)

  1. Predictors of prenatal and postpartum care adequacy in a medicaid managed care population.
    Weir S, Posner HE, Zhang J, et al. · Womens Health Issues · 2012 · Background
    PubMed: PMID 21565526 · NCT06367465 · Hepatitis C

2007 (1 paper)

  1. Predictors of compliance with the postpartum visit among women living in healthy start project areas.
    Bryant AS, Haas JS, McElrath TF, et al. · Matern Child Health J · 2007 · Background
    PubMed: PMID 16807794 · NCT06367465 · Hepatitis C

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).